Drugs / TAF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05771402 Background | Oct 2023 → Dec 2026 expected | autoimmune pulmonary disease due to PD-1 deficiency, chronic hepatitis B virus infection, interferon antiviral depressor | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | “ETV/TDF/TAF” NCT05771402 ↗ |
| Modality | Other / unclassified | “nucleos(t)ide analogues (NAs)” NCT05771402 ↗ |
| Route | Oral | “Once/day, 1 capsule/time, oral” NCT05771402 ↗ |